Subscribe our newsletter here and get 10%* off your next purchase! (terms & conditions*)

About IBA Lifesciences

IBA Lifesciences GmbH is a biotechnology company providing products for life science research in academia and industry. We develop high performance research tools for cell and protein isolation based on our proprietary Strep-tag® technology. Situated in Göttingen, Germany, we have built a network of worldwide distributors making our products available in over 40 countries across 5 continents.  

IBA Team

Managing Director, Chief Executive Officer

Mike Rothe has extensive biotech industry experience and expertise in building successful life science companies. His involvement in biotechnology started as a visiting scientist at Genentech, Inc. (South San Francisco, USA) in 1992. From 1994 to early 1999, he was a Staff Scientist and Team Leader at Tularik, Inc. (South San Francisco, USA). In 1999, Dr. Rothe joined DeveloGen AG (Göttingen, Germany) as Vice President, Research and Development and later served as its Chief Scientific Officer. In July 2001, he co-founded U3 Pharma AG (Munich, Germany) and assumed the roles of Managing Director and CSO. He was instrumental in the acquisition of U3 Pharma by Daiichi Sankyo in 2008. From 2009 to 2012 he served as CEO and Member of the Board of Directors of Igenica, Inc. (Burlingame, USA). Prior to joining IBA GmbH, he was CEO of ImmunoQure AG (Munich, Germany) and CEO and Delegate of the Board of Directors of ImmunoQure Research AG (Zurich, Switzerland). Dr. Rothe studied biochemistry at the University of Tübingen before receiving his Ph.D. from the University of Munich and being awarded the Otto-Hahn Medal of the Max-Planck-Society. He is the author of numerous scientific articles and international patents.

Managing Director, Chief Quality Officer

Joachim Bertram received his Ph.D. in microbiology in the department of Prof. Gottschalk at the University of Goettingen. Then he moved to the department of hematology and oncology headed by Prof. Hiddemann where he has held a number of positions of increasing seniority in the biomedical profession. He conducted scientific and applied research on the use of antisense oligonucleotides and ribozymes in the field of proliferative diseases. In addition he focussed on mechanisms of drug resistance development and the use of nucleic acid based compounds for growth factor mimicry. In 1998, Joachim Bertram finished his "habilitation" in the medical faculty. He joined IBA Lifesciences GmbH in January 2000 and became CEO of IBA Biologics in 2001.

Over the last two decades, Herbert Stadler has built a track record as one of Germany's most active biotech entrepreneurs. He has founded or co founded several companies including Biometra GmbH, Ribonetics GmbH, HepaVec AG, IBA GmbH and DeveloGen AG. Herbert Stadler is a neurochemist by training. He obtained his Ph.D. at the Freie University of Berlin, obtained his postdoctoral lecture qualification ("Habilitation") at the University of Göttingen and headed the Molecular Neurobiology Group at the Max-Planck Institute of Biophysical Chemistry in Göttingen. He currently serves on the supervisory boards of DeveloGen AG and IBA Lifesciences GmbH.

Dr. Fabian Mohr
Chief Scientific Officer
Research & Development
Dr. Christos Gouloudis
Dr. Franziska Hartung
Anna Färger
Director Marketing
Dr. Isabel Schuchardt
Director Product Management
Scarlett Döring

If you are interested in working at IBA Lifesciences and you'd like to join our team, please check open vacancies:

View current vacancies


Coming from Kassel or Hannover (A7) take exit "Göttingen Nord". After 500 m take exit "Holtensen", in the roundabout take the second exit into August-Spindler-Straße, then immediately turn left again into Rudolf-Wissell-Straße. IBA GmbH is the second complex of buildings on the left.

Coming from Göttingen downtown, location main station/ Romantik Hotel Gebhards, take the "Berliner Straße" towards A7 Hannover/Kassel and turn right into "Groner Landstraße". Immediately after crossing the bridge over the river turn right into "Königsallee" towards "Adelebsen", follow it passing two roundabouts. After 1.9 km turn left into “Elliehäuser Weg”, go straight ahead for 900 m, turn right into Rudolf-Wissell-Straße”, follow the road and pass the left turn. 100 m onward you find IBA Lifesciences GmbH in the complex of buildings on the right. We recommend taking a cab from the main station to IBA Lifesciences GmbH (takes about 10 minutes).

ISO 9001:2015 Quality Management Standard certification

Being the most recognized quality management standard in the world, ISO 9001:2015 is designed to help organizations to ensure that they meet the needs of customers and employees. It recognizes that the policies, practices and procedures of a company consistently result in high quality products and services which are provided to their customers.

Dr. Joachim Bertram, Managing Director at IBA, discusses receipt of the certificate: “Since 2004, IBA’s production and customer service fulfilled the high level of the ISO demands and standard procedures. However, gaining this accreditation now enables us to really demonstrate and highlight our high quality performance to our customers”.

IBA Lifesciences GmbH is dedicated to providing high quality tools for life science research and supports customers from early discovery to commercialization in industry and academia. The company offers solutions for the entire production chain of recombinant proteins, from cloning, transfection, protein expression and purification, to detection, immobilization and assays.

We also deliver new tools for immunology research, including a growing line of tag-based reagents for cell isolation.

Download ISO 9001 certificate here.

Funded research projects


BioNanoSPION - Entwicklung eines neuartigen Produktionsverfahrens für Nanobodies in E. coli.

Das Ziel des vorliegenden Projektvorhabens besteht in der Entwicklung eines neuartigen Produktionsverfahrens für Nanobodies auf Basis einer bakteriellen Hochzelldichtekultivierung, das einen integrierten Aufreinigungsschritt mithilfe magnetischer Partikel (SPIONs: Superparamagnetic Iron Oxide Nanoparticles) beinhaltet. Durch die Kopplung von Nanobodies und SPIONs über die von der IBA entwickelte Strep-tag®/Strep-Tactin® Technologie entstehen Nanobody-SPION-Konjugate, die eine einfache Abtrennung der Nanobodies aus dem Kulturmedium im Verlauf des Herstellungsprozesses ermöglichen. Zusätzlich zu diesem innovativen, prozessintegrierten Aufreinigungsschritt werden die Nanobody-SPION-Konjugate direkt als Produkt für die Zellisolierung auf den Markt gebracht. Die magnetischen Eigenschaften der SPIONs können somit sowohl für die Nanobody-Produktgewinnung als auch für die spätere Anwendung als Forschungsreagenz zur Zellisolierung genutzt werden.

FKZ 16KN053647

FKZ 16KN053647: MS Multi Mat – Membran App/Membranapplikation – Zellreinigungskartuschen mit innovativen Trägern


FKZ 13FH6K01IA: Innovativer Ansatz zur Wundbehandlung auf Basis eines Zell-/Exosome Sprays – KMU – Skin-Las

FKZ 16KN053641

FKZ 16KN053641: MS Multi Mat – BioReg – Polymer-Protein-Scaffold zur Zellreinigung

Nr. ZW3 – 85021564

Antrags-Nr. ZW3 – 85021564: Entwicklung neuer Verfahren zur gezielten Erzeugung spezifischer Einzeldomänen-Antikörper mit niedriger Bindungs-Affinität

FKZ 03VNE2046D

FKZ 03VNE2046D: Entwicklung einer adaptierbaren, molekularen Strategie zur Qualitätskontrolle zellbasierter Therapien; Teilprojekt: Fab-Streps & Aktivierungsmarker (ZellTherQC)

FKZ 03RU1U091B

FKZ 03RU1U091B: Entwicklung von funktionalisierten Magnetpartikeln und Farbstoffkonjugaten zur Isolierung und Detektion von Spermien